The Centers for Disease Control and Prevention today released updated guidance for clinicians treating COVID-19 in patients who received the Pfizer COVID-19 antiviral pill Paxlovid. 

“There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected,” CDC said, noting that a brief return of symptoms may be part of the natural history of SARS-CoV-2 infection in some individuals, “independent of treatment with Paxlovid and regardless of vaccination status.”

CDC continues to recommend Paxlovid to treat mild to moderate COVID-19 in patients at high risk for progressing to severe disease and isolating patients when COVID-19 rebounds to manage transmission risk.

Related News Articles

Headline
In a study of symptomatic adults tested for SARS-CoV-2 at U.S. pharmacies since Sept. 14, bivalent COVID-19 vaccine boosters provided additional protection…
Headline
The Biden Administration today launched a six-week campaign to encourage Americans to get an updated COVID-19 vaccine. In addition to ongoing pop-up clinics,…
Headline
Children under age 5 are more likely to receive a COVID-19 vaccine if their parents perceive it as safe and their health care provider recommends it, according…
Headline
AHA this week released a new Thanksgiving-focused toolkit to help promote pediatric COVID-19 vaccination on social media, including sample content and graphics…
Headline
The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected…
Headline
Black patients who sought outpatient care for COVID-19 between January and July 2022 were 36% less likely than white patients to receive the antiviral pill…